[1] Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA:A Cancer Journal for Clinicians. 2018;68:394-424.
[2] Stahl M, Stuschke M, Lehmann N, Meyer H-J, Walz MK, Seeber S. Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus. 2005;23:2310-7.
[3] Robb WB, Messager M, Dahan L, Mornex F, Maillard E, D'Journo XB, et al. Patterns of recurrence in early-stage oesophageal cancer after chemoradiotherapy and surgery compared with surgery alone. The British journal of surgery. 2016;103:117-25.
[4] Haefner MF, Lang K, Krug D, Koerber SA, Uhlmann L, Kieser M, et al. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. Journal of radiation research. 2015;56:742-9.
[5] Ordu AD, Nieder C, Geinitz H, Kup PG, Deymann LF, Scherer V, et al. Radio(chemo)therapy for locally advanced squamous cell carcinoma of the esophagus: long-term outcome. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]. 2015;191:153-60.
[6] Shioyama Y, Nakamura K, Ohga S, Nomoto S, Sasaki T, Yamaguchi T, et al. Radiation therapy for recurrent esophageal cancer after surgery: clinical results and prognostic factors. Japanese journal of clinical oncology. 2007;37:918-23.
[7] Balermpas P, Keller C, Hambek M, Wagenblast J, Seitz O, Rodel C, et al. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results. International Journal of Radiation Oncology biology physics. 2012;83:e377-83.
[8] Sohda M, Kuwano H. Current Status and Future Prospects for Esophageal Cancer Treatment. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia. 2017;23:1-11.
[9] Ashraf TM, Nabi MG, Ali ZS, Wajahat A. Comparative evaluation between re-irradiation and demand endoscopic dilatation vs endoscopic dilatation alone in patients with recurrent/reactivated residual in-field esophageal malignancies. Journal of cancer research and therapeutics. 2008;4:121-5.
[10] Yamaguchi S, Ohguri T, Imada H, Yahara K, Moon SD, Higure A, et al. Multimodal approaches including three-dimensional conformal re-irradiation for recurrent or persistent esophageal cancer: preliminary results. Journal of radiation research. 2011;52:812-20.
[11] Kim YS, Lee CG, Kim KH, Kim T, Lee J, Cho Y, et al. Re-irradiation of recurrent esophageal cancer after primary definitive radiotherapy. Radiation oncology journal. 2012;30:182-8.
[12] Chen Y, Lu Y, Wang Y, Yang H, Xia Y, Chen M, et al. Comparison of salvage chemoradiation versus salvage surgery for recurrent esophageal squamous cell carcinoma after definitive radiochemotherapy or radiotherapy alone. Dis Esophagus. 2014;27:134-40.
[13] Zhou ZG, Zhen CJ, Bai WW, Zhang P, Qiao XY, Liang JL, et al. Salvage radiotherapy in patients with local recurrent esophageal cancer after radical radiochemotherapy. Radiation oncology (London, England). 2015;10:54.
[14] Katano A, Yamashita H, Nakagawa K. Re-irradiation of locoregional esophageal cancer recurrence following definitive chemoradiotherapy: A report of 6 cases. Molecular and clinical oncology. 2017;7:681-6.
[15] Hong L, Huang Y-X, Zhuang Q-Y, Zhang X-Q, Tang L-R, Du K-X, et al. Survival benefit of re-irradiation in esophageal Cancer patients with Locoregional recurrence: a propensity score-matched analysis. Radiation oncology (London, England). 2018;13:171-.
[16] Chen HY, Ma XM, Ye M, Hou YL, Xie HY, Bai YR. Esophageal perforation during or after conformal radiotherapy for esophageal carcinoma. Journal of radiation research. 2014;55:940-7.
[17] Versteijne E, van Laarhoven HW, van Hooft JE, van Os RM, Geijsen ED, van Berge Henegouwen MI, et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus. 2015;28:453-9.
[18] Lin SH, Chang JY. Esophageal cancer: diagnosis and management. Chinese journal of cancer. 2010;29:843-54.
[19] Takiar V, Garden AS, Ma D, Morrison WH, Edson M, Zafereo ME, et al. Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses. International journal of radiation oncology, biology, physics. 2016;95:1117-31.
[20] Sminia P, Mayer R. External beam radiotherapy of recurrent glioma: radiation tolerance of the human brain. Cancers (Basel). 2012;4:379-99.
[21] Yoshiaki O, Masao M, Eisaku Y, Ryohei S, Yoshishige O, Toshifumi N, et al. Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. International Journal of Radiation Oncology
biology physics. 2002;52:390–6.
[22] de Rezende ACP, Weltman E, Chen MJ, Helito JK, de Carvalho IT, Sakuraba RK, et al. Intensity-modulated ventricular irradiation for intracranial germ-cell tumors: Survival analysis and impact of salvage re-irradiation. PLoS One. 2019;14:e0226350.
[23] van der Meij W, Rombouts AJ, Rutten H, Bremers AJ, de Wilt JH. Treatment of Locally Recurrent Rectal Carcinoma in Previously (Chemo)Irradiated Patients: A Review. Dis Colon Rectum. 2016;59:148-56.
[24] Al-Haidari G, Skovlund E, Undseth C, Rekstad BL, Larsen SG, Asli LM, et al. Re-irradiation for recurrent rectal cancer - a single-center experience. Acta Oncol. 2020:1-7.
[25] Tsang DS, Laperriere NJ. Re-irradiation for Paediatric Tumours. Clin Oncol (R Coll Radiol). 2019;31:191-8.
[26] Xu X, Wang Z, Jiang S, Shang Y, Wu Y. Evaluating the optimal re-irradiation dose for locally recurrent esophageal squamous cell carcinoma after definitive radiotherapy. Radiation oncology (London, England). 2019;14:191.
[27] Yu E, Tai P, Malthaner R, Stitt L, Rodrigues G, Dar R, et al. What are the factors that predict outcome at relapse after previous esophagectomy and adjuvant therapy in high-risk esophageal cancer? Current oncology (Toronto, Ont). 2010;17:46-51.
[28] Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20:1167-74.
[29] Deng HY, Li G, Luo J. Does oesophageal stenosis have any impact on survival of oesophageal cancer patients? Interactive cardiovascular and thoracic surgery. 2018;27:384-6.
[30] Tsushima T, Mizusawa J, Sudo K, Honma Y, Kato K, Igaki H, et al. Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer: A Supplementary Analysis of JCOG0303. Medicine. 2016;95:e3699.
[31] Kawakami T, Tsushima T, Omae K, Ogawa H, Shirasu H, Kito Y, et al. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study. BMC Cancer. 2018;18:573.
[32] Watanabe S, Ogino I, Kunisaki C, Hata M. Relationship between nutritional status and esophageal fistula formation after radiotherapy for esophageal cancer. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 2019;23:222-7.
[33] Xu Y, Wang L, He B, Li W, Wen Q, Wang S, et al. Development and validation of a risk prediction model for radiotherapy-related esophageal fistula in esophageal cancer. Radiation oncology (London, England). 2019;14:181.